Galera Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _______ to _______Commission File Number: 001-39114 Galera Therapeutics, Inc.(Exact name of registrant as specified in its charter) (610) 725-1500(Registrant’s telephone number, including area code) N/A(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 12, 2026, the registrant had 160,429,783 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)1Consolidated Balance Sheets1Consolidated Statements of Operations2Consolidated Statements of Changes in Redeemable Convertible Preferred Stock andStockholders’ Equity (Deficit)3Consolidated Statements of Cash Flows4Notes to Unaudited Interim Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk24Item 4.Controls and Procedures24PART II.OTHER INFORMATIONItem 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds27Item 3.Defaults Upon Senior Securities27Item 4.Mine Safety Disclosures27Item 5.Other Information27Item 6.Exhibits28Signatures29 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harborprovisions of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities ExchangeAct of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this QuarterlyReport on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”“predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-lookingstatements contain these words. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements, including, without limitation, statements regarding our forthcoming merger with ObsidianTherapeutics, Inc. and concurrent Private Investment in Public Equity financing; the impact of our discontinuation of the developmentof all but one of our product candidates; the sufficiency of our cash and cash equivalents and our ability to raise additional capital tofund our operations; and the plans and objectives of management for future operations. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on ourcurrent expectations and projections about future events and financial trends that we believe may affect our business, financialcondition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause actual results to differmaterially from th